{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
10X Genomics, Inc.
10X Genomics Hits Day High with 9.65% Surge in Intraday Performance
10X Genomics, Inc. experienced a notable stock price increase on October 31, 2025, despite facing a challenging year with a significant decline. The company has high institutional ownership but struggles with negative financial metrics, indicating ongoing profitability issues amid a volatile market environment.
10X Genomics, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
10X Genomics, Inc. has recently seen a stock price of $11.60, reflecting volatility over the past year with a high of $18.21 and a low of $6.78. The company has faced significant challenges, with a notable decline in stock performance compared to the S&P 500 over various timeframes.
Is 10X Genomics, Inc. technically bullish or bearish?
As of October 10, 2025, 10X Genomics, Inc. shows a mildly bearish trend with key indicators confirming a negative outlook, despite a slightly bullish daily moving average, and has underperformed the S&P 500 significantly year-to-date and over the past year.
Is 10X Genomics, Inc. technically bullish or bearish?
As of October 10, 2025, 10X Genomics, Inc. shows a mildly bearish trend with negative indicators across multiple time frames, underperforming the S&P 500 with a year-to-date return of -20.13%.
Is 10X Genomics, Inc. technically bullish or bearish?
As of October 10, 2025, 10X Genomics, Inc. shows a mildly bearish trend due to bearish signals from MACD, KST, and Bollinger Bands, despite daily moving averages indicating mild bullishness, with the stock underperforming the S&P 500 significantly year-to-date and over the past year.
10X Genomics Hits Day Low of $11.54 Amid Price Pressure
10X Genomics, Inc. has faced significant stock price declines, with a year-to-date drop of 19.22% and a 41.5% decrease over the past year. Despite reporting strong operating cash flow and high institutional ownership, the company struggles with negative EBITDA and long-term underperformance compared to the S&P 500.
10X Genomics Experiences Evaluation Revision Amidst Market Dynamics and Performance Challenges
10X Genomics, Inc. has recently revised its evaluation amid ongoing market challenges, with its stock price at $13.04. Over the past year, the company has experienced significant volatility, reflected in a return of -44.46%. Technical indicators show mixed signals, highlighting the need for careful performance monitoring.
Is 10X Genomics, Inc. technically bullish or bearish?
As of September 2, 2025, 10X Genomics, Inc. shows a mildly bullish trend with mixed technical indicators, while underperforming the S&P 500 with a year-to-date return of -7.59% compared to 12.22% for the index.
Is 10X Genomics, Inc. technically bullish or bearish?
As of June 10, 2025, 10X Genomics, Inc. is in a sideways trend with mixed technical signals, showing mild bullishness on some indicators but bearishness on others, indicating a lack of strong directional movement.
Who are in the management team of 10X Genomics, Inc.?
As of March 2022, the management team of 10X Genomics, Inc. includes Mr. John Stuelpnagel (Independent Chairman), Dr. Benjamin Hindson (President, Co-Founder, Chief Scientific Officer), Mr. Serge Saxonov (CEO, Co-Founder), and several independent directors, ensuring a diverse governance structure.
What does 10X Genomics, Inc. do?
10X Genomics, Inc. is a life science technology company specializing in integrated solutions for biological analysis, with a recent net sales of $155 million and a market cap of $1.32 billion. The company reported a net loss of $34 million as of March 2025.
How big is 10X Genomics, Inc.?
As of Jun 18, 10X Genomics, Inc. has a market capitalization of 1,318.41 million, with net sales of 624.65 million and a net profit of -157.04 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
